Literature DB >> 16001118

Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist.

Jackie Cilia1, Jane E Cluderay, Melanie J Robbins, Charlie Reavill, Eric Southam, James N C Kew, Declan N C Jones.   

Abstract

RATIONALE: The alpha7 subtype of the nicotinic receptor plays an important role in auditory sensory gating. Schizophrenics show deficient sensory gating and abnormalities in the number and regulation of nicotinic receptors. Prepulse inhibition (PPI) deficits exhibited by isolation-reared rats are thought to model the sensorimotor gating deficits seen in schizophrenia.
OBJECTIVE: To examine the role of nicotinic alpha7 receptors in the isolation-rearing rat model, we tested whether the selective alpha7 receptor agonist (R)-N-(1-Azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (compound A) could reverse isolation-rearing-induced PPI deficits, and investigated alpha7 receptor RNA expression in the hippocampus, prefrontal cortex, cerebellum, nucleus accumbens and thalamus, and alpha7 receptor protein expression in the hippocampus of isolation- and group-reared rats.
METHOD: Rats reared in isolation or groups of five from weaning were tested in the PPI paradigm under conditions of variable inter-stimulus interval (ISI) (pulse = 110 dB/50 ms; prepulse = 75 dB/30 ms; ISI = 30, 100 and 300 ms) 30 min following administration of compound A (3.2-10 mg/kg i.p.). Alpha7 receptor expression was measured by TaqMan RT-PCR (total RNA) and autoradiography (protein).
RESULTS: Isolation-rearing-induced PPI deficits were attenuated by both doses of compound A at 100-ms ISI and by 10 mg/kg at 300-ms ISI. Expression of alpha7 receptor RNA and protein was unaltered in isolation-reared rats.
CONCLUSION: Although altered alpha7 receptor expression may not underlie the phenotype of isolation-reared rats, the activation of these receptors may be of benefit in re-establishing efficient gating function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001118     DOI: 10.1007/s00213-005-0069-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  Nicotinic receptors, smoking and schizophrenia.

Authors:  S Leonard; J Gault; C Adams; C R Breese; Y Rollins; L E Adler; A Olincy; R Freedman
Journal:  Restor Neurol Neurosci       Date:  1998-06       Impact factor: 2.406

2.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

3.  Impaired prepulse inhibition of acoustic startle in schizophrenia.

Authors:  A Parwani; E J Duncan; E Bartlett; S H Madonick; T R Efferen; R Rajan; M Sanfilipo; P B Chappell; S Chakravorty; S Gonzenbach; G N Ko; J P Rotrosen
Journal:  Biol Psychiatry       Date:  2000-04-01       Impact factor: 13.382

Review 4.  Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon.

Authors:  N R Swerdlow; D L Braff; M A Geyer
Journal:  Behav Pharmacol       Date:  2000-06       Impact factor: 2.293

Review 5.  Sensorimotor gating and schizophrenia. Human and animal model studies.

Authors:  D L Braff; M A Geyer
Journal:  Arch Gen Psychiatry       Date:  1990-02

6.  Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input.

Authors:  H S Hoffman; J R Ison
Journal:  Psychol Rev       Date:  1980-03       Impact factor: 8.934

7.  Gating and habituation of the startle reflex in schizophrenic patients.

Authors:  D L Braff; C Grillon; M A Geyer
Journal:  Arch Gen Psychiatry       Date:  1992-03

8.  Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors.

Authors:  A R Davies; D J Hardick; I S Blagbrough; B V Potter; A J Wolstenholme; S Wonnacott
Journal:  Neuropharmacology       Date:  1999-05       Impact factor: 5.250

9.  Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.

Authors:  A J Grottick; G Trube; W A Corrigall; J Huwyler; P Malherbe; R Wyler; G A Higgins
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

10.  DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.

Authors:  Heidi C O'Neill; Kate Rieger; William R Kem; Karen E Stevens
Journal:  Psychopharmacology (Berl)       Date:  2003-05-21       Impact factor: 4.530

View more
  15 in total

1.  Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.

Authors:  Sung Won Kim; Yu-Shin Ding; David Alexoff; Vinal Patel; Jean Logan; Kuo-Shyan Lin; Colleen Shea; Lisa Muench; Youwen Xu; Pauline Carter; Payton King; Jasmine R Constanzo; James A Ciaccio; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2007-07       Impact factor: 2.408

2.  Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice.

Authors:  J W Young; J M Meves; I S Tarantino; S Caldwell; M A Geyer
Journal:  Genes Brain Behav       Date:  2011-07-07       Impact factor: 3.449

Review 3.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 4.  Effect of second-generation antipsychotics on cognition: current issues and future challenges.

Authors:  S Kristian Hill; Jeffrey R Bishop; Donna Palumbo; John A Sweeney
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

Review 5.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

6.  Identification of targeted analyte clusters for studies of schizophrenia.

Authors:  Tammy M K Cheng; Yu-En Lu; Paul C Guest; Hassan Rahmoune; Laura W Harris; Lan Wang; Dan Ma; Victoria Stelzhammer; Yagnesh Umrania; Matt T Wayland; Pietro Lió; Sabine Bahn
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

Review 7.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

8.  Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.

Authors:  Jared W Young; Jessica M Meves; Mark A Geyer
Journal:  Behav Brain Res       Date:  2012-11-29       Impact factor: 3.332

Review 9.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

10.  Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice.

Authors:  Ken Koda; Yukio Ago; Toshiyuki Kawasaki; Hitoshi Hashimoto; Akemichi Baba; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2007-10-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.